Aryloxypiperidine Pyrazole IDO Inhibitors for Restoring T-Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Indoleamine 2,3-dioxygenase (IDO) activity leads to immunosuppression, tumor resistance, and various diseases such as autoimmune disorders, HIV infection, and fetal tolerance, necessitating inhibitors to enhance T-cell activation and treat associated diseases.

Innovation Solution

Development of novel arylpiperidine pyrazole compounds that act as potent inhibitors of the IDO enzyme, potentially reversing immunosuppressive effects and enhancing T-cell activation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If IDO activity is increased to suppress T-cell responses and promote tolerance, then immune tolerance is improved, but T-cell activation is suppressed

Engineering Contradiction:

Improveimmune toleranceVSAvoidT-cell suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful immunosuppressive effect of IDO activity into a beneficial therapeutic outcome by developing specific inhibitors that block IDO. The inhibitors transform the pathogenic tryptophan catabolism into a controlled process, restoring T-cell function while maintaining the ability to induce tolerance when needed, thus converting a harmful mechanism into a treatable target

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the biochemical parameters of tryptophan metabolism by inhibiting IDO enzyme activity. This parameter change prevents the conversion of tryptophan to kynurenine, thereby altering the immunomodulatory environment and restoring T-cell activation without completely eliminating tolerance mechanisms

Inventive Principle:

Principle #35Parameter changes

2Reliability

If IDO activity is increased to prevent fetal rejection, then fetal tolerance is improved, but T-cell mediated immunity is suppressed

Engineering Contradiction:

Improvefetal toleranceVSAvoidT-cell immunity suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial inhibition of IDO activity rather than complete blockade, allowing sufficient tryptophan catabolism to maintain fetal tolerance while preventing excessive suppression of T-cell immunity. This balanced approach ensures that the therapeutic intervention achieves the desired immune modulation without over-correcting and causing adverse effects

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If IDO activity is increased to suppress T-cell responses in autoimmune diseases, then immune suppression is improved, but disease progression worsens due to loss of immune control

Engineering Contradiction:

Improveimmune suppressionVSAvoiddisease progression

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs a feedback mechanism where IDO inhibition restores T-cell surveillance and immune control, which then regulates autoimmune responses dynamically. The restored T-cell function provides negative feedback on overactive immune cells, automatically adjusting immune suppression levels to prevent disease progression while maintaining necessary immune tolerance

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS12576087B2Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Publication Date: 2026.03.17 MERCK SHARP & DOHME LLC

AI summary

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.